[go: up one dir, main page]

AR099625A1 - Anticuerpos de il-21 - Google Patents

Anticuerpos de il-21

Info

Publication number
AR099625A1
AR099625A1 ARP150100643A ARP150100643A AR099625A1 AR 099625 A1 AR099625 A1 AR 099625A1 AR P150100643 A ARP150100643 A AR P150100643A AR P150100643 A ARP150100643 A AR P150100643A AR 099625 A1 AR099625 A1 AR 099625A1
Authority
AR
Argentina
Prior art keywords
seq
antibody
sequence
chains
mammalian cell
Prior art date
Application number
ARP150100643A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR099625A1 publication Critical patent/AR099625A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 1: Un anticuerpo que se une a IL-21 humana caracterizado porque comprende una región variable de cadena pesada (HCVR) y una región variable de cadena ligera (LCVR) en donde la LCVR comprende la SEQ ID Nº 7 en la CDRL1, la SEQ ID Nº 8 en la CDRL2 y la SEQ ID Nº 9 en la CDRL3 y en donde la HCVR comprende la SEQ ID Nº 10 en la CDRH1, la SEQ ID Nº 11 en CDRH2 y la SEQ ID Nº 12 en la CDRH3. Reivindicación 5: Una molécula de ADN caracterizada. porque comprende un polinucleótido que codifica la cadena pesada de anticuerpo cuya secuencia de aminoácido es la secuencia de la SEQ ID Nº 3. Reivindicación 11: Una célula de mamífero transformada con la molécula de ADN de conformidad con la reivindicación 5 o reivindicación 6 y la molécula de ADN de conformidad con la reivindicación 7 o reivindicación 9, caracterizada porque la célula de mamífero transformada es capaz de expresar un anticuerpo que comprenden dos cadenas pesadas de anticuerpo y dos cadenas ligeras de inmunoglobulina, en las cuales la secuencia amino de cada una de las dos cadenas pesadas es la secuencia de la SEQ ID Nº 3 y la secuencia de aminoácido de cada una de las dos cadenas ligeras es la secuencia de la SEQ ID Nº 4. Reivindicación 13: Un proceso para producir un anticuerpo, en el cual el anticuerpo comprende dos cadenas pesadas de anticuerpo y dos cadenas ligeras de inmunoglobulina, en las cuales la secuencia amino de cada una de las dos cadenas pesadas es la secuencia de la SEQ ID Nº 3 y la secuencia de aminoácido de cada una de las dos cadenas ligeras es la secuencia de la SEQ ID Nº 4, y caracterizado porque comprende: a) cultivar la célula de mamífero de la reivindicación 11 o la célula de mamífero de la reivindicación 12 bajo condiciones de manera que el anticuerpo es expresado, y b) recuperar el anticuerpo expresado. Reivindicación 15: Un método para tratar una condición autoinmune en un paciente, caracterizado porque comprende administrar una dosis efectiva del anticuerpo de conformidad con cualquiera de las reivindicaciones 1 a 4 ó 14 al paciente. Reivindicación 24: Una composición farmacéutica caracterizada porque comprende el anticuerpo de conformidad con cualquiera de las reivindicaciones 1, 2, ó 12 y un excipiente farmacéuticamente aceptable.
ARP150100643A 2014-03-21 2015-03-04 Anticuerpos de il-21 AR099625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
AR099625A1 true AR099625A1 (es) 2016-08-03

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100643A AR099625A1 (es) 2014-03-21 2015-03-04 Anticuerpos de il-21

Country Status (24)

Country Link
US (1) US9394362B2 (es)
EP (1) EP3119806B1 (es)
JP (2) JP6053989B2 (es)
KR (1) KR101859857B1 (es)
CN (1) CN106061999B (es)
AP (1) AP2016009450A0 (es)
AR (1) AR099625A1 (es)
AU (1) AU2015231777B2 (es)
BR (1) BR112016019176A2 (es)
CA (1) CA2939543C (es)
CL (1) CL2016002281A1 (es)
EA (1) EA033335B1 (es)
EC (1) ECSP16075416A (es)
ES (1) ES2774422T3 (es)
IL (1) IL246909A0 (es)
MA (1) MA39342B2 (es)
MX (1) MX2016012120A (es)
MY (1) MY177915A (es)
NZ (1) NZ722518A (es)
PE (1) PE20161221A1 (es)
PH (1) PH12016501820A1 (es)
SG (1) SG11201606705QA (es)
TW (1) TWI646105B (es)
WO (1) WO2015142637A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3128997T3 (da) * 2014-04-08 2020-08-24 Boston Pharmaceuticals Inc Bindingmolekyler specifikke for il-21 og anvendelser deraf
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3436060A4 (en) * 2016-03-31 2019-12-04 Eli Lilly and Company IL-21 ANTIBODIES AND USES THEREOF
EP3801558A4 (en) * 2018-05-31 2022-03-09 Glycom A/S HMOS BLEND FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規il-21プロドラッグおよびその使用方法
KR20240035824A (ko) * 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309028A1 (en) 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
EP4367147A1 (en) * 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258562B1 (en) * 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN102040662A (zh) * 2003-03-14 2011-05-04 惠氏有限责任公司 抗人il-21受体的抗体及其应用
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
PL2796466T3 (pl) * 2007-12-07 2018-04-30 Zymogenetics, Inc. Humanizowane cząsteczki przeciwciała swoiste dla il-31
JP5745274B2 (ja) * 2007-12-07 2015-07-08 ザイモジェネティクス, インコーポレイテッド 抗ヒトil−21モノクローナル抗体
CN103443124A (zh) 2011-01-17 2013-12-11 诺沃—诺迪斯克有限公司 Il-21配体
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
JP2017093435A (ja) 2017-06-01
ES2774422T3 (es) 2020-07-21
EP3119806A1 (en) 2017-01-25
MA39342A1 (fr) 2018-03-30
CN106061999A (zh) 2016-10-26
CL2016002281A1 (es) 2017-06-23
WO2015142637A1 (en) 2015-09-24
CA2939543C (en) 2018-01-16
TW201623330A (zh) 2016-07-01
EA201691521A1 (ru) 2017-02-28
NZ722518A (en) 2017-12-22
BR112016019176A2 (pt) 2017-10-10
EP3119806A4 (en) 2017-11-01
TWI646105B (zh) 2019-01-01
ECSP16075416A (es) 2018-05-31
PH12016501820A1 (en) 2016-11-07
SG11201606705QA (en) 2016-09-29
JP2016520088A (ja) 2016-07-11
JP6373944B2 (ja) 2018-08-15
KR101859857B1 (ko) 2018-05-18
MY177915A (en) 2020-09-25
AP2016009450A0 (en) 2016-09-30
AU2015231777A1 (en) 2016-08-18
JP6053989B2 (ja) 2017-01-11
MA39342B2 (fr) 2020-03-31
EP3119806B1 (en) 2020-01-01
KR20160124166A (ko) 2016-10-26
PE20161221A1 (es) 2016-11-12
CA2939543A1 (en) 2015-09-24
MX2016012120A (es) 2016-12-09
EA033335B1 (ru) 2019-09-30
AU2015231777B2 (en) 2017-08-03
US9394362B2 (en) 2016-07-19
CN106061999B (zh) 2020-07-31
IL246909A0 (en) 2016-09-29
US20150266954A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
AR099625A1 (es) Anticuerpos de il-21
JP2020500538A5 (es)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR105654A1 (es) Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
RU2019118359A (ru) Антитело к cd73 человека
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
AR101875A1 (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
PE20170687A1 (es) Proteinas de enlace a cd127
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
AR086579A1 (es) Proteinas de union a antigeno
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
AR097651A1 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR102592A1 (es) Anticuerpos biespecíficos y métodos de uso en oftalmología
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas

Legal Events

Date Code Title Description
FB Suspension of granting procedure